Shandong Tefaman Pharmaceutical Co Ltd.

Primary objective: To evaluate the pharmacokinetic characteristics of unchanged TPN729MA tablets and its metabolite TPN-M3 in male subjects with different degrees of hepatic insufficiency and healthy subjects after a single dose. Secondary objectives: (1) To evaluate the safety of unchanged TPN729MA tablets in male subjects with different degrees of hepatic insufficiency and healthy subjects after a single dose. (2) To evaluate the plasma protein binding rate of unchanged TPN729MA tablets and its metabolite TPN-M3 in male subjects with different degrees of hepatic insufficiency and healthy subjects after a single dose.

Primary objective: To evaluate the pharmacokinetic characteristics of the original TPN729MA tablets and its metabolite TPN-M3 in male subjects with different degrees of renal insufficiency and healthy subjects after a single dose. Secondary objectives: 1) To evaluate the safety of TPN729MA tablets in male subjects with different degrees of renal insufficiency and healthy subjects after a single dose; 2) To evaluate the plasma protein binding rate of the original TPN729MA tablets and its metabolite TPN-M3 in male subjects with different degrees of renal insufficiency and healthy subjects after a single dose.

Primary objective: To evaluate the pharmacokinetic (PK) characteristics of unchanged TPN729MA tablets and its metabolite TPN-M3 in elderly male subjects (age ≥ 65 years) after a single dose. Secondary objectives: 1) To evaluate the safety of TPN729MA tablets in elderly male subjects (age ≥ 65 years) after a single dose. 2) To evaluate the plasma protein binding rate of unchanged TPN729MA tablets and its metabolite TPN-M3 in elderly male subjects (age ≥ 65 years) after a single dose.